3 Stocks To Buy Without Wasting Time - Ocugen

1- Ocugen

Ocugen Inc, formerly Histogenics Corporation, is a clinical-stage biotechnology firm focused on discovering, developing and gaining commercial benefit from treatments for eye diseases. What adds value to Ocugen's value is their investment in gene therapies and development with the aim of curing blindness. Blindness improvement trials have not yet entered the Phase 1 clinical test. A company that is in the beginning stages of achieving an impossible success in theory already has a market value of $1.77 billion.

So How Did It Succeed?

It turns out that Ocugen could earn a billion-dollar return on the coronavirus vaccine. Its partner, Bharat Biotech, has developed an 81 percent effective coronavirus vaccine (COVAXIN) that has received regulatory approvals in India. Bharat Biotech and Ocugen requested an emergency use permit from the US Food and Drug Administration for their vaccine, COVAXIN. Partner companies are planning to sell around 100 million doses of COVAXIN in the US from the second quarter of 2021. If a successful approval process is carried out, Ocugen receives 45 percent of the profit, a figure that is likely to reach $1 billion according to the current pricing environment. Ocugen is an innovative biotech company that can invest its profits in improving gene therapies. The coronavirus vaccine (COVAXIN) creates a great opportunity to fund Ocugen's own research. There are so many reasons for biotech investors to add Ocugen to their portfolio!   3 Stocks To Buy Without Wasting Time - Ocugen Source: https://www.fool.com/ You may also be interested in:

3 Stocs To Buy From Warren Buffet's Portfolio – T-Mobile